

In The Claims

This listing of the claims will replace all prior versions, and listings, of claims in the application.

1-54. (Canceled).

55. (Previously Presented) A composition of matter comprising:

a conjugate of a nonextracellular matrix protein, nonlabeling agent and a carboxamide-carrying linking molecule,

wherein the agent is selected from the group consisting of an anti-nerve gas agent, an anti-neurotoxin agent and an antiglaucoma agent,

wherein the agent is not itself a substrate of transglutaminase,

wherein the agent, free of conjugation to the linking molecule, does not contain the linking molecule, and

wherein the linking molecule comprises at least two contiguous linked glutamines, and is a substrate of transglutaminase.

56. (Canceled).

57. (Previously Presented) The composition of claim 55, wherein the linking molecule comprises a polymer of amino acids containing at least 20% glutamines.

58.-65. (Canceled).

66. (Previously Presented) A composition of matter comprising:

a conjugate of a nonextracellular matrix protein, nonlabeling agent and a polymer,

wherein the agent is selected from the group consisting of an anti-nerve gas agent, an anti-neurotoxin agent and an antiglaucoma agent,

wherein the agent is not itself a substrate of transglutaminase, and

wherein the polymer comprises at least 3 contiguous lysines attached to one another by peptide bonds, and is a substrate of transglutaminase.

67. (Previously Presented) The composition of claim 66, wherein the polymer is a polymer of amino acids, wherein at least 20% of the amino acids are lysines.

68-70. (Canceled).

71. (Previously Presented) A kit comprising
a package housing:
a first container containing the composition of claim 55 and
a second container containing transglutaminase.

72.-73. (Canceled).

74. (Previously Presented) The composition of claim 55, wherein the linking molecule comprises at least 5 linked units, each unit being a carboxamide-bearing substrate for transglutaminase.

75. (Previously Presented) The composition of claim 55, wherein the linking molecule is 4 or more contiguous glutamines attached directly to one another by peptide bonds.

76.-77. (Canceled).

78. (Previously Presented) The composition of claim 55, wherein the agent is selected from the group consisting of a cholinesterase and a phosphodiesterase.

79. (Previously Presented) The composition of claim 55, wherein the agent is conjugated to the linking molecule by a bond that is hydrolyzable under physiological conditions.

80.-82. (Canceled).

83. (Previously Presented) The composition of claim 66, wherein the agent is conjugated to the linking molecule by a bond that is hydrolyzable under physiological conditions.

84.-85. (Canceled).

86. (Previously Presented) The kit of claim 71, further comprising
a third container housed by said package, the third container containing a linking molecule that is a substrate of transglutaminase and that is capable of covalently attaching to the composition contained in the first container in the presence of transglutaminase when the composition and the linking molecule are removed from the containers and contacted with each other.

87. (Previously Presented) The kit of claim 71, further comprising calcium housed by said package, except that said calcium is not in said second container.

88. (Previously Presented) A kit comprising
a package housing:
a first container containing the composition of claim 66, and
a second container containing transglutaminase.

89. (Previously Presented) The kit of claim 88, further comprising
a third container housed by said package, the third container containing a linking molecule that is a substrate of transglutaminase and that is capable of covalently attaching to the composition contained in the first container in the presence of transglutaminase when the composition and the linking molecule are removed from the containers and contacted with each other.

90. (Previously Presented) The kit of claim 88, further comprising calcium housed by said package, except that said calcium is not in said second container.

91.-100. (Canceled).

101. (Previously Presented) The composition of claim 66, wherein the agent is selected from the group consisting of a cholinesterase and a phosphodiesterase.

102-103. (Canceled).

104. (Previously Presented) The composition of claim 55, wherein the linking molecule comprises at least three contiguous linked glutamines.

105. (Previously Presented) The composition of claim 55, wherein the linking molecule comprises at least four contiguous linked glutamines.

106. (Previously Presented) The composition of claim 55, wherein the linking molecule comprises at least five contiguous linked glutamines.

107. (Previously Presented) The composition of claim 55, wherein the linking molecule comprises a polymer of amino acids containing at least 30% glutamines.

108. (Previously Presented) The composition of claim 55, wherein the linking molecule comprises a polymer of amino acids containing at least 40% glutamines.

109. (Previously Presented) The composition of claim 66, wherein the polymer comprises at least 4 contiguous lysines attached to one another by peptide bonds.

110. (Previously Presented) The composition of claim 66, wherein the polymer comprises at least 5 contiguous lysines attached to one another by peptide bonds.

111. (Previously Presented) The composition of claim 66, wherein the polymer is a polymer of amino acids, wherein at least 30% of the amino acids are lysines.

112. (Previously Presented) The composition of claim 66, wherein the polymer is a polymer of amino acids, wherein at least 40% of the amino acids are lysines.

113. (Previously Presented) The composition of claim 55, wherein the agent is an anti-nerve gas agent.

114. (Previously Presented) The composition of claim 55, wherein the agent is an anti-neurotoxin agent.

115. (Previously Presented) The composition of claim 55, wherein the agent is an antiglaucoma agent.

116. (Previously Presented) The composition of claim 66, wherein the agent is an anti-nerve gas agent.

117. (Previously Presented) The composition of claim 66, wherein the agent is an anti-neurotoxin agent.

118. (Previously Presented) The composition of claim 66, wherein the agent is an antiglaucoma agent.

119. (New) A kit comprising
a package housing:
a first container containing the composition of any one of claims 104, 109 and 113-118,
and
a second container containing transglutaminase.